A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...
The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...
Everyday Health on MSN
New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight
The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...
Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...
Starting Jan. 1, 2026, Pennsylvania will limit GLP‑1 weight‑loss drugs under Medicaid — threatening access for thousands of ...
Social media adverts for weight loss drugs have been banned by the Advertising Standards Authority, which has condemned some ...
An advert which targeted weight-loss injections at new mums has been banned by the Advertising Standards Authority (ASA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback